Track the Ascendis Pharma A/S stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €17bn. The latest transaction was disclosed on 18 August 2026 (Acquisition). Among the most active insiders: BIENAIME JEAN JACQUES. Every trade is free.
10
Insider Decl.
n/a
Thresholds
€671,606
9 ops.
Buy Volume
€4m
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ascendis Pharma A/S Strong Buy (bullish), based on 18 analysts. Average price target: US$313.06.
42Σ signal
Buys €671,606€4m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,349 of 28,835 companies
50.2
score / 100
Value
34
Quality
66
FCF yld0.3%
Earn yld-1.4%
EV/EBITDA·
ROE119%
Gross mgn87%
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
19,460 shares@ US$238.4903100.0% of flowOrdinary SharesSEC:0001610717-26-000159:0
10 of 10 declarations
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company focused on developing innovative treatments for endocrine diseases and other medical conditions. It utilizes its drug technology platform to create peptide-based therapies.